Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Antioxidant Therapy for Cardioprotection in AMI Patients
NCT05215743Phase 1Completed
- Sponsor
- Universidad de Chile
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of deferoxamine, acetylcysteine and ascorbic acid in acute myocardial infarction (AMI) and reperfusion injury (IRI) (2 arms), sponsored by Universidad de Chile. Primary endpoints: Peak plasma concentration at 180 minutes, Half-life time at 180 minutes and 5 more. Started Aug 2022; status: completed.
02
Drugs
deferoxamineacetylcysteineascorbic acid
03
Conditions
acute myocardial infarction (AMI)reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT05215743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215743.